세계의 당뇨병성 황반부종 치료 시장

Global Diabetic Macular Edema Treatment Market to Reach US$5.5 Billion by 2030

The global market for Diabetic Macular Edema Treatment estimated at US$4.8 Billion in the year 2024, is expected to reach US$5.5 Billion by 2030, growing at a CAGR of 2.2% over the analysis period 2024-2030. Anti-VEGF, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Corticosteroid segment is estimated at 2.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 1.9% CAGR

The Diabetic Macular Edema Treatment market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$855.8 Million by the year 2030 trailing a CAGR of 1.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.2% and 1.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Diabetic Macular Edema Treatment Market - Key Trends & Drivers Summarized

What Is Diabetic Macular Edema and Why Is Effective Treatment Critical?

Diabetic Macular Edema (DME) is a severe eye condition that affects individuals with diabetes, leading to swelling in the macula, the central part of the retina responsible for sharp vision. As diabetes prevalence rises globally, DME has become an increasingly common complication, posing a significant risk of vision loss if left untreated. Effective treatment for DME is crucial as it directly impacts the quality of life for millions of patients by preserving their vision and enabling them to maintain independence. Current treatment options include intravitreal injections of anti-VEGF agents, corticosteroids, and laser therapy, each targeting different aspects of the disease's pathology. As research advances, newer therapies are being developed to improve efficacy, reduce side effects, and provide more sustained relief for patients suffering from this debilitating condition.

How Are Advancements in Treatment Technologies Improving DME Outcomes?

Advancements in medical technologies and pharmacology are significantly improving the outcomes for patients with Diabetic Macular Edema. The introduction of anti-VEGF (vascular endothelial growth factor) therapies has revolutionized DME treatment, offering a more targeted approach to managing the condition by inhibiting the abnormal blood vessel growth that leads to macular swelling. These therapies have been shown to significantly improve visual acuity and reduce retinal thickness. Additionally, sustained-release corticosteroid implants have emerged as a promising option for patients who do not respond adequately to anti-VEGF treatments, providing long-term management with fewer injections. Furthermore, ongoing research into gene therapy and other novel approaches aims to address the underlying causes of DME, potentially offering more durable and comprehensive treatment solutions in the future.

What Challenges Exist in Managing Diabetic Macular Edema?

Managing Diabetic Macular Edema presents several challenges, both for patients and healthcare providers. One of the primary challenges is the chronic nature of the condition, which requires ongoing monitoring and repeated treatments to maintain visual function. Adherence to treatment regimens can be difficult for patients, especially when frequent intravitreal injections are necessary, leading to potential lapses in care and suboptimal outcomes. Additionally, the variability in response to current treatments underscores the need for personalized approaches to DME management, as some patients may not experience sufficient improvement with standard therapies. Another challenge is the accessibility and affordability of advanced treatments, particularly in low- and middle-income countries, where the burden of diabetes and its complications is growing rapidly.

Growth in the Diabetic Macular Edema Treatment Market Is Driven by Several Factors

The growth in the Diabetic Macular Edema treatment market is driven by several factors, including the rising global prevalence of diabetes, advancements in treatment technologies, and increased awareness and screening for diabetic eye diseases. As the diabetic population continues to expand, the demand for effective DME treatments is expected to rise correspondingly. Technological innovations, such as the development of longer-acting anti-VEGF agents and sustained-release drug delivery systems, are also fueling market growth by offering improved treatment options with fewer side effects and greater patient convenience. Additionally, public health initiatives aimed at early detection and intervention for diabetic retinopathy and macular edema are increasing the number of diagnosed cases, further driving the demand for treatment. These factors, combined with ongoing research into new therapeutic modalities, are poised to shape the future landscape of DME treatment, making it a rapidly evolving and dynamic market.

SCOPE OF STUDY:

The report analyzes the Diabetic Macular Edema Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Anti-VEGF, Corticosteroid, Other Products)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 38 Featured) -

• AbbVie, Inc.
• Alimera Sciences, Inc.
• Bausch & Lomb, Inc.
• Boehringer Ingelheim International GmbH
• Genentech, Inc.
• IRIDEX Corporation
• Novartis International AG
• Pfizer, Inc.
• Quantel Medical
• Regeneron Pharmaceuticals, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Diabetic Macular Edema Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
  • Global Economic Update
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Diabetes Drives Growth in Diabetic Macular Edema Treatment Market
  • Technological Advancements in Ophthalmic Imaging Propel Demand for Early Diagnosis and Treatment
  • Increased Government Funding for Diabetes-related Research Expands Addressable Market for Treatments
  • Rising Awareness of Diabetic Eye Complications Spurs Demand for Advanced Treatment Options
  • Emergence of Novel Therapeutics Strengthens Business Case for Targeted Treatments
  • Technological Innovations in Drug Delivery Systems Propel Growth in Injectable Treatments
  • Expanding Availability of Anti-VEGF Therapies Drives Adoption in Diabetic Macular Edema Treatment
  • Improved Patient Outcomes with Combination Therapies Accelerates Treatment Adoption
  • Increasing Investment in Biologics Spurs Growth in Long-lasting DME Treatment Solutions
  • Rising Focus on Minimally Invasive Treatments Generates Demand for Innovative Surgical Solutions
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 2: World Historic Review for Diabetic Macular Edema Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 3: World 15-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 5: World Historic Review for Anti-VEGF by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 6: World 15-Year Perspective for Anti-VEGF by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 7: World Recent Past, Current & Future Analysis for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 8: World Historic Review for Corticosteroid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 9: World 15-Year Perspective for Corticosteroid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 11: World Historic Review for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 12: World 15-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
  • TABLE 13: World Diabetic Macular Edema Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 14: USA Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 15: USA Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: USA 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 17: Canada Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 18: Canada Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: Canada 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• JAPAN
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 20: Japan Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 21: Japan Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: Japan 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• CHINA
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 23: China Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 24: China Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: China 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• EUROPE
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 26: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: Europe Historic Review for Diabetic Macular Edema Treatment by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 29: Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 30: Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• FRANCE
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 32: France Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: France Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: France 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• GERMANY
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 35: Germany Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: Germany Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: Germany 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 38: Italy Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Italy Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: Italy 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 41: UK Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: UK Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: UK 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 44: Rest of Europe Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Rest of Europe Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: Rest of Europe 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Diabetic Macular Edema Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 47: Asia-Pacific Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Asia-Pacific Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: Asia-Pacific 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030
• REST OF WORLD
  • TABLE 50: Rest of World Recent Past, Current & Future Analysis for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Rest of World Historic Review for Diabetic Macular Edema Treatment by Product - Anti-VEGF, Corticosteroid and Other Products Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Rest of World 15-Year Perspective for Diabetic Macular Edema Treatment by Product - Percentage Breakdown of Value Sales for Anti-VEGF, Corticosteroid and Other Products for the Years 2015, 2025 & 2030

IV. COMPETITION